Dimerix has adopted a partnering strategy in which one or more partners will be identified with the expertise and resources to advance products to market. Dimerix plans to build strategic alliances across commercial, clinical and manufacturing areas at the appropriate stage of development. These collaborations will enhance the potential for the success of Dimerix product candidates, which will mitigate capital obligations and commercial risk.
Partnering with Dimerix
Excellerate Bioscience - 2019
License Agreement for Excellerate to provide Receptor-HIT assay as a service to leading pharmaceutical and biotechnology companies, as well as academic institutes, as part of its world-class expertise in assay technology.
Dimerix has licensed its proprietary Receptor-HIT assay to Excellerate Bioscience, a UK-based pharmacological assay service provider. Under the non-exclusive Agreement, Excellerate will offer Receptor-HIT to leading pharmaceutical and biotechnology companies, as well as academic institutes, as part of its world-class expertise in assay technology for which Dimerix will receive an undisclosed royalty on gross revenues of the service fee.
Excellerate Bioscience is a dynamic and innovative organisation, built on a worldwide reputation for excellence in the field of molecular and cellular pharmacology.
Based in BioCity Nottingham UK, the company applies state of the art pharmacological theory and technology to improve the efficiency and translatability of in vitro pharmacological profiling, providing solutions to some of the world’s leading pharmaceutical and biotechnology companies, as well as globally-recognised academic institutions.
Harry Perkins Institute of Medical Research and University of Western Australia (UWA) – 2018
Professor Kevin Pfleger
Collaborative program to carry out molecular pharmacology profiling of targets of interest to Dimerix.
The research project will be overseen by Professor Kevin Pfleger, Head of Molecular Endocrinology and Pharmacology at the Perkins and Chief Scientific Advisor to Dimerix.
The profiling of molecular biology targets is aligned with Dimerix’s Receptor-HIT platform from which lead development candidate DMX-200, currently in two phase 2 clinical trials for Diabetic Kidney Disease and for Focal Segmental Glomerulosclerosis, was developed.
The collaboration is funded, in part, by an Innovation Connections Grant (Australian Government’s Department of Industry, Innovation and Science), and leverages the expertise of Professor Kevin Pfleger, one of the inventors of the Receptor-HIT platform. The program continues the strong relationship Dimerix has with the Harry Perkins Institute of Medical Research and University of Western Australia, which have state-of-the-art equipment and methodology ideally suited to the program.
